Senna

contact (stimulant) laxative, anthraquinone glycoside (A06AB)

Also sold as Senokot, Ex-Lax, Senexon, Perdiem, Black Draught.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Senna has no classical depletion machinery of the enzyme-induction, chelation or transporter-competition kind. Sennosides are glycoside prodrugs that reach the colon largely unabsorbed, where gut bacteria produce rhein anthrone, described as the ultimate active form [7]; the monograph reference describes minimal absorption and a stimulation of colonic cyclic AMP, fluid and ion secretion [4], and the two OTC labels retrieved carry no pharmacokinetic, interaction or nutrient section [1][2]. The one signal with a Tier A source is potassium, and it runs as a fecal-loss disturbance, not a dietary shortfall: in a randomized trial of 73 hemodialysis patients, 8 weeks of senna glycoside lowered pre-dialysis serum potassium by 0.32 mEq/L against 0.02 mEq/L with control [10]. Frank hypokalemia with chronic overuse is documented only at case and small-series level, mostly with mixed laxatives [11][12][13][14]. That entry is graded orange with its boundary stated, and it is an excess-loss risk: taking potassium because of senna is not the remedy this dossier supports. No entry reaches red, because no second independent Tier A source exists.

contact (stimulant) laxative, anthraquinone glycoside (A06AB) · ATC A06AB06 (senna glycosides) · also sold as Senokot and Ex-Lax and Senexon and Perdiem and Black Draught; many OTC generics · reviewed 2026-10-04. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Senna in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Potassium: serum lowering in a hemodialysis RCT (8 weeks); hypokalemia with chronic overuse reported at case level only

Orange — Moderate

Evidence in: Tier A (bounded)

In 73 patients on maintenance hemodialysis, 8 weeks of senna glycoside lowered pre-dialysis serum potassium by about 0.3 mEq/L against control. Frank hypokalemia is described only in case reports and small series of chronic laxative abuse, mostly with mixed agents. This is a fecal-loss disturbance, not a dietary shortfall.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. Orange, Tier A (bounded)

Limits on what this shows

Key null findings: In the same trial the prevalence of hyperkalemia was not reduced (13.8% senna vs 5.4% control, p = 0.309) [10]. A 28-day placebo-controlled trial in 90 patients with chronic constipation (senna 1.0 g as reported, magnesium oxide 1.5 g, placebo) reported 0% severe treatment-related adverse events, but its abstract reports no serum electrolyte data, so it is neither a null nor a positive potassium result [25]. A colonoscopy-preparation trial of 342 patients adding senna to magnesium citrate also reports no electrolyte data in its abstract [26].
At-risk subgroups: Patients on maintenance hemodialysis (where the effect was measured and may be intended, as the trial was designed to lower potassium); people with chronic high-dose or prolonged use and persistent diarrhea; people also taking digoxin or other potassium-lowering drugs (background statement in [27], not a tested result).

Regulatory status

No potassium statement in the label fields retrieved for the syrup or the 15 mg tablet [1][2]. The monograph and a side-effect reference list hypokalemia among effects of chronic use [4][5].

Population evidence

Tier A: Nata et al., randomized controlled trial, hemodialysis patients, senna glycoside n = 37 vs control n = 36, 8 weeks. Primary outcome pre-dialysis serum potassium: change -0.32 mEq/L (reported 95% CI -0.43 to -0.04) with senna vs -0.02 mEq/L (-0.12 to 0.05) with control, p < 0.001; hyperkalemia prevalence 13.8% vs 5.4% (p = 0.309); no serious adverse events [10]. Read through an OpenAlex-reconstructed abstract; the paper is closed access and the full text, the senna product, the dose and the baseline potassium were not opened. The printed confidence interval sits close to its upper bound relative to the point estimate and is reported as printed. Senna is the studied drug, so the cohort test is met. Tier B/C support for chronic overuse: one woman with chronic Folia Sennae abuse, severe hypokalemia with muscle weakness and raised CPK, LDH and GOT, normalized after parenteral potassium [11]; seven women with laxative-induced diarrhoea, hypokalaemia frequent, senna preparations identified by biopsy in three [12]; nine chronic purgative-abusing women with hypokalaemia, agents unspecified in the abstract [13]; a review noting low potassium in concealed anthraquinone and phenolphthalein abuse [14]. [12][13][14] do not isolate senna and are class or mixed-agent evidence.

Mechanism

Named and plausible: stimulant-driven colonic fluid and ion secretion with shortened transit [4]; the trial authors state senna may decrease colonic transit time and potassium reabsorption [10]. Renal tubular wasting is not described.

Editorial note

Orange is assigned on the literal test: Tier A, senna in the cohort, potassium directly measured, a definable subgroup and exposure window. The measured change is a modest lowering in patients who tend toward high potassium, so it is a pharmacologic disturbance and not itself a deficiency; an editor may re-grade. Frank hypokalemia in people using senna as labeled is not shown by any source retrieved.

Draft customer string

In a trial of people on hemodialysis, 8 weeks of senna lowered blood potassium by about 0.3 mEq/L; low potassium is reported with long-term overuse. Ask a clinician before using senna regularly or with heart or kidney medicines.

Counter-evidence held on record

Counter-evidence on record Confounding by indication is presumed (Hard Rule 6): the dialysis cohort starts from a different potassium baseline than general users, and the abuse reports involve concealed multi-agent use, vomiting and possible diuretic use, so none isolates senna. No study of senna at labeled doses in general adults with potassium as the outcome was retrieved. The single trial has no independent replication in the retrieved record, which is why the grade is not red. Framing caution This is excess potassium loss through the gut, not a diet shortfall (Hard Rule 5). It is not an instruction to increase potassium intake, and supplementation would be the hazard, not the remedy. No dose is given anywhere in this dossier. Persistent diarrhea or muscle weakness warrants clinician review.

Fluid, sodium and acid-base disturbance with chronic overuse (context flag)

Yellow — Low

Evidence in: Tier B/C

Reference texts and small abuse series describe dehydration, water-balance and acid-base disturbance with prolonged or high-dose use. No study measuring sodium, bicarbonate or hydration with senna at labeled doses was retrieved.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, Tier B/C

Limits on what this shows

Key null findings: Placebo-controlled 28-day trial of senna in chronic constipation, 0% severe treatment-related adverse events, no electrolyte data in the abstract [25]. In constipated mice, the laxative effect diminished after 7 days with only slight colon damage by 14 to 21 days [19].
At-risk subgroups: People with persistent diarrhea from high-dose or prolonged use; people with concealed laxative use; older adults (MedlinePlus advises against long-term use at 65 and over [6]).

Regulatory status

No such statement in the label fields retrieved; the labels limit use to 1 week unless directed by a doctor for the syrup [1][2].

Population evidence

Reference text only for senna: the monograph states that prolonged use may cause persistent diarrhea, loss of essential nutritional factors and dehydration, and lists electrolyte disturbances including metabolic acidosis or alkalosis [4]; a side-effect reference lists electrolyte metabolism disorder, water equilibrium disorder, tetany and cachexia with chronic use [5]. No primary citations were visible in the retrieved text. Class and small-series support (Tier C where senna is not isolated): seven women with laxative-induced diarrhoea and frequent electrolyte abnormalities attributed to severe diarrhoea and vomiting [12]; nine purgative abusers with hypokalaemia, hypomagnesaemia and hypophosphataemia, and after withdrawal temporary oedema in seven [13].

Mechanism

The intended secretory and transit action carried to excess (Hard Rule 2): fluid loss from persistent diarrhea. Filed as a context flag, not a depletion mechanism at labeled doses.

Counter-evidence held on record

Counter-evidence on record Confounding by indication and co-use of other laxatives, diuretics, vomiting and poor intake are not separated in any retrieved source (Hard Rule 6). The list of effects in [4][5] is generic stimulant-laxative wording whose senna specificity is unverified. Framing caution This is a fluid and electrolyte loss disturbance tied to overuse, not a dietary shortfall. It does not mean sodium, bicarbonate or fluids should be added without a clinician. Persistent diarrhea warrants clinician review.

Calcium: reference-text caution only, no measurement

Yellow — Low

Evidence in: Tier B

A professional monograph lists hypocalcemia among electrolyte disturbances with chronic use, and a side-effect reference lists tetany. No study measured calcium with senna.

Full detail and limits

Limits on what this shows

Key null findings: No calcium measurement with senna was found, so there is no PTH or companion-marker check available. Hypocalcemia and tetany are disturbance outcomes and are not filed as a calcium deficiency (Hard Rule 2).
At-risk subgroups: People with persistent diarrhea from prolonged use.

Regulatory status

The 15 mg tablet label states each tablet contains calcium 40 mg, a content statement and not a depletion effect [2]. No calcium effect statement in the label fields retrieved [1][2].

Population evidence

None. Reference text only, no design, sample size or effect estimate [4][5]. A consultancy list names calcium among nutrients depleted by a group of laxatives including senna, without citations [28]; a clinic handout lists calcium and potassium for bisacodyl laxatives and does not list senna [29]. Both are Tier D claim origins and support nothing.

Mechanism

Not specific. The mechanism class would be fluid and electrolyte loss with overuse; no calcium-specific mechanism (for example a PTH axis effect) is described in any retrieved source.

Counter-evidence held on record

Counter-evidence on record The monograph wording is generic stimulant-laxative text without a primary citation, so senna specificity is unverified. Shares its source with the fluid entry and the potassium entry (see Overlap map). Framing caution This is a disturbance flag for overuse. It is not a reason to take calcium, and no dose is given.

Magnesium: class extrapolation from mixed purgative-abuse cases

Yellow — Low

Evidence: Tier C (class extrapolation)

Hypomagnesaemia was reported in a small series of chronic purgative abusers whose agents are not specified in the retrieved abstract. No senna-specific magnesium measurement was found.

Full detail and limits

Limits on what this shows

Key null findings: Two senna trials reported no electrolyte data in their abstracts [25][26]. The magnesium oxide arm in [25] is a comparator drug and not evidence of a senna effect on magnesium.
At-risk subgroups: Chronic high-dose or concealed users.

Regulatory status

No magnesium statement in the label fields retrieved [1][2].

Population evidence

Tier C. Meyers 1990: nine chronic purgative-abusing women, hypokalaemia, hypomagnesaemia and hypophosphataemia, creatine kinase inversely related to potassium and phosphate (r = -0.86, P < 0.03) [13]. Agents are not detailed in the abstract, so whether senna was in the cohort is unknown, and the cohort test fails for senna. A review of laxative abuse names phenolphthalein and anthraquinone derivatives as the most commonly abused and low potassium in concealed abuse, but its retrieved abstract does not name magnesium [14].

Mechanism

Not stated. Gastrointestinal and renal losses with purgative abuse are the usual class-level explanation but are not demonstrated in the retrieved text.

Counter-evidence held on record

Counter-evidence on record Mixed-agent abuse, vomiting, diuretics and malnutrition confound the series; n = 9 and one report. Used only as a labeled class extrapolation and capped at yellow. Framing caution This is a possible disturbance with severe overuse and not a recommendation to take magnesium. No dose is given.

Melanosis coli: drug tissue effect, not a nutrient

Yellow — Low

Evidence in: Tier B (outcome entry)

Prolonged anthraquinone laxative use, including sennosides, pigments the colonic mucosa; it is described as benign and reversible after stopping. It is entered as an outcome and not as a nutrient finding.

Full detail and limits

Limits on what this shows

Key null findings: A meta-analysis of colorectal neoplasms in melanosis coli (Katsumata 2021) was listed but no abstract could be read, so it is not used. No nutrient was measured in any of these sources.
At-risk subgroups: Longer or higher-dose users; children in the one cohort cited secondhand.

Regulatory status

Not in the OTC label fields retrieved [1][2]. The monograph says the drug may discolor colonic mucosa, described as innocuous and reversible, and warns of cathartic colon with chronic misuse [4]; a side-effect reference says pseudomelanosis coli usually recedes on discontinuation [5].

Population evidence

Review level. A Frontiers in Pharmacology review reports, citing primary papers that were not opened here, that children taking sennosides for functional constipation had melanosis coli with an adjusted odds ratio of 13.88 (Chen 2022), that sennoside at 100 mg/kg/day for 12 weeks induced lipofuscin deposition and colonic melanosis (Shen 2017), and that sennosides induced colonic epithelial apoptosis via p53 and p21 (van Gorkom 2001); remission is reported 6 months to 1 year after stopping anthraquinones generally, with no senna-specific timeline [24]. In rats, long-term anthraquinone use produced melanosis coli [8]. A review of laxative abuse links prolonged anthraquinone use to melanosis coli [14]. The review was read through a summarizing fetch tool; the primary Tier A cohort was not opened, which is why this is not graded above yellow.

Mechanism

Reported as apoptosis of colonic epithelial cells with pigment accumulation [24]; rhein was proposed to cause chronic toxicity through apoptosis and autophagy [8].

Counter-evidence held on record

Counter-evidence on record This is a drug effect on tissue under Hard Rule 2 and is not a nutrient entry. Prevalence figures in users depend on indication and duration and were not verified from primary papers. Framing caution This is a benign-appearing tissue change reported on colonoscopy. It carries no supplement or nutrient implication, and this dossier makes no cancer-risk claim.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden: reverse direction, protective in rodent obesity models

Yellow — Low

Evidence in: Tier B

In high-fat-diet mice, purified sennoside A reversed mitochondrial structural damage and respiratory-complex abnormalities. No study of sennosides on mitochondria in healthy tissue or in people was retrieved.

Full detail and limits

Limits on what this shows

Key null findings: Vitalone 2011: senna leaf extract standardized to 60% sennosides in healthy Wistar rats at 12 and 58 mg/kg/day for 4 to 8 weeks produced no change in liver function or histology (abstract-level; mitochondria were not specifically measured) [21].
At-risk subgroups: None identified.

Regulatory status

No mitochondrial statement in the label fields retrieved [1][2].

Population evidence

Tier B, sennoside A itself, one research group. Le 2018, male C57BL/6 mice on a high-fat diet: the diet caused cristae loss, swelling, vacuolization and outer-membrane rupture, complex I activation with complex II and IV deficiency, and higher VDAC1 and tissue ATP; sennoside A reversed these effects and the authors propose VDAC1 inhibition as the mechanism [15]. Ma 2020, diet-induced obese mice, oral sennoside A: lower mitochondrial ROS through inhibition of complexes I and III with higher Mn-SOD activity, and inhibition of PINK1/Parkin mitophagy in colon [16]. Le 2019 (30 mg/kg/day, 8 weeks) reports the same pattern in enterocytes [17]. Abstracts or summaries only, read through ScienceDirect and fetch tools; doses for [15] and [16], group sizes and effect estimates were not retrieved. Cohort test: senna sennoside A is the test article.

Metabolite note (Tier C)

In rats, rhein, the metabolite that accumulated most with chronic sennoside A exposure, was proposed to cause chronic toxicity through apoptosis and autophagy; the abstract does not mention mitochondrial dysfunction [8]. PubMed lists 117 records for rhein and mitochondria, but the first ten were mostly conjugate drugs for cancer or unrelated papers and none was opened, so none is used.

Mechanism

Named in the studies: VDAC1 and complex I and III inhibition [15][16]. The direction is normalization of a diet-induced abnormality, and the same complex inhibition could carry a different meaning in healthy tissue, which no retrieved study tests.

Counter-evidence held on record

Counter-evidence on record All three positive studies share one laboratory and one disease model (high-fat diet) and the third overlaps the first two in endpoints, so they are one line of evidence (see Overlap map). Obese-mouse tissue is not a model for people using senna for constipation. Framing caution This is a laboratory signal that runs opposite to harm. It is not a nutrient deficiency, not a mitochondrial toxicity claim and not a reason to recommend senna or any supplement.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress: reverse direction in disease models; a pro-oxidant signal only for the rhein metabolite

Yellow — Low

Evidence in: Tier B/C

Sennoside A and sennoside B lowered oxidative markers in rodent disease models, and a senna leaf extract did not induce oxidative stress in healthy rats. Pure rhein, a sennoside metabolite, raised reactive oxygen species in a mouse embryo study after intravenous dosing.

Full detail and limits

Limits on what this shows

Key null findings: The healthy-rat extract study found no induction [21]. No human redox marker was measured with senna in any retrieved source.
At-risk subgroups: None identified. The rhein embryo signal concerns pregnancy only in an intravenous mouse model; the labels advise asking a health professional in pregnancy [1][2].

Regulatory status

No oxidative-stress statement in the label fields retrieved [1][2].

Population evidence

Tier B, sennoside A: lower mitochondrial ROS and higher Mn-SOD in obese-mouse colon [16]. Tier B, sennoside B: in Sprague-Dawley rats with pentylenetetrazole seizures, malondialdehyde lower and superoxide dismutase higher with sennoside B, dose-dependently (abstract via OpenAlex) [22]. A sennoside A sepsis-kidney-injury paper (Peng 2025) is listed with oxidative and ferroptosis endpoints but only metadata was read, so it is not used. Null: no oxidative stress induction with a 60% sennoside Cassia angustifolia extract in healthy rats, 12 and 58 mg/kg/day for 4 to 8 weeks [21]. Cohort test: senna sennosides were tested in [16][21][22].

Class extrapolation (metabolite, Tier C)

Huang 2017: rhein incubated with mouse blastocysts caused cell death and fewer inner-cell-mass cells; intravenous injection in pregnant mice raised ROS and lowered antioxidant protein expression in fetal liver [23]. This is pure rhein, intravenous, in embryos, not oral senna; whether oral senna produces comparable systemic rhein exposure was not established in the sources retrieved. Labeled as a metabolite extrapolation. No emodin or aloe-emodin source was used.

Mechanism

Reduced mitochondrial ROS via complex I and III inhibition and Mn-SOD [16]; the rhein pro-oxidant effect is described only for the pure metabolite [23].

Counter-evidence held on record

Counter-evidence on record Disease-model protection and healthy-animal null results point away from a pro-oxidant effect, while the metabolite study points toward one at unrealistic route and form; the net is unresolved. Shared source with Mitochondrial burden and ATP production for [16]. Framing caution This is not an antioxidant deficiency and not a reason to take antioxidants. Do not read the rodent protective findings as a benefit claim for senna.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on copper absorption, status or ceruloplasmin with senna in people or animals. This is a disclosed gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to senna was found to support even a yellow grade, and no circulating copper claim for senna was located in the two consumer documents audited [28][29] to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap on the PubMed channel that answered; consumer-claim searching was tooling-limited because web search was exhausted. Kept separate from Iron.

Regulatory status

The two OTC labels retrieved (syrup 8.8 mg per 5 mL; tablet 15 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

PubMed listing 'senna copper' returned 6 records: a herbal-supplement metal-content survey, a fluorescent copper nanocluster detection method, a Senna italica phytochemistry paper, a Cassia angustifolia stem-cell burn-healing paper, a fungal copper-stress plant study and a phytoremediation survey. None measured copper status in an animal or person exposed to senna; plant copper content is not an effect of the drug.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'senna copper' (6 records, none relevant); PubMed listing 'senna iron' (16 records, none on copper); OpenAlex works-search and Europe PMC REST (429, no results); consumer documents [28][29] read for any copper claim (none). Network state this review: per the review brief, direct HTTP to PubMed, eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar, Unpaywall, DailyMed and accessdata.fda.gov is blocked by organization network policy (403 on CONNECT) and was neither attempted nor routed around. Through the fetch tool: PubMed search-listing pages answered intermittently with repeated 429 rate-limit rejections (waits of 60 to 110 seconds between queries), and PubMed single-article pages returned blank or bot-check content; Europe PMC REST returned 429 on both attempts; OpenAlex works-search returned 429 on both attempts while OpenAlex single-record lookups by PMID worked; one ScienceDirect page returned 429 and answered on a single retry; NCBI Bookshelf returned a reCAPTCHA page; the DailyMed search page returned no labels and the openFDA label API was used instead; the EMA herbal monograph URL tried returned 404; Crossref, Semantic Scholar and Unpaywall were not attempted; the web-search budget (200 of 200) was already exhausted, so no web search could be run. No email address or other identifying information was sent to any service. See the access note under Sources.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with senna in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk: rodent data with mixed direction, no human in vivo study

Yellow — Low

Evidence in: Tier B

Purified sennoside A shifted gut bacterial composition in three mouse studies, favorably in obesity models and with diversity falling after the first week in constipated mice. One ex vivo human-stool study of a different Senna seed extract showed strong taxon-specific effects and is a labeled class extrapolation.

Full detail and limits

Limits on what this shows

Key null findings: No human in vivo microbiome study of senna was retrieved. The 2020 db/db paper measured no oxidative stress or electrolyte markers and does not discuss limitations [18]. No composition data were retrieved for the labeled clinical dose in people.
At-risk subgroups: None identified. The day-14 to day-21 decline in diversity and colon damage in mice [19] corresponds to the labels' 1-week limit [1][2], without any human confirmation.

Regulatory status

No microbiome statement in the label fields retrieved [1][2].

Population evidence

Tier B, sennoside A itself. Le 2019, high-fat-diet obese mice, 30 mg/kg/day in drinking water for 8 weeks: Firmicutes reduced, Firmicutes/Bacteroidetes ratio normalized, Clostridiales, Desulfovibrionaceae and Oscillospira reduced, the butyrate producer Allobaculum decline partly prevented, short-chain fatty acids partly restored [17]. Wei 2020, db/db mice, 25 and 50 mg/kg by gavage for 12 weeks: Odoribacter, Turicibacter, Akkermansia, SMB53 and Mucispirillum increased, AF12, Oscillospira and Ruminococcus decreased; fecal transfer carried the metabolic benefit [18]. Zhang 2023, constipated mice, 2.6 mg/kg orally for 1 to 21 days: microbial diversity peaked at day 7 then declined, with Lactobacillus, Romboutsia, Akkermansia and UCG_005 implicated, and the laxative effect diminished with slight colon damage at 14 to 21 days [19]. A fourth abstract reports that sennoside A for 2 months ameliorated gut dysbiosis in APP/PS1 mice, with no taxa read [31]. All were read as abstracts or summaries through fetch tools [17][18][19] or OpenAlex [31]; sample sizes and confidence intervals were not retrieved.

Class extrapolation (Tier C)

Narrowe 2024: an ethanol extract of Juemingzi (seeds of Senna obtusifolia or Senna tora), not the Senna alexandrina sennoside product, incubated at 3 g/L for 48 hours with stool from 6 healthy adults in an ex vivo system: Bacteroidota sharply reduced (the OpenAlex abstract says about 40%; the full-text summary says nearly eliminated, mean 1.3%, a discrepancy not resolved here), acetate up, butyrate and valerate down. Sennosides and emodin were not individually quantified, and the dose is described as high-end [20]. Cohort test: senna sennosides were not isolated in this cohort, so it is Tier C and used only as a labeled class extrapolation; no emodin or aloe-emodin source was used.

Mechanism

Partly characterized: colonic bacteria convert sennosides to rhein anthrone [7], and in rats fecal flora from treated animals converted sennoside A to rhein more efficiently, so exposure alters the flora that handle the drug [8]. A causal route to any nutrient outcome is not shown.

Counter-evidence held on record

Counter-evidence on record Obesity, diabetes and Alzheimer mouse models differ from healthy or constipated people, and favorable shifts in those models are not evidence of harm or benefit in users. Constipation itself alters the microbiome and is presumed to confound any human comparison (Hard Rule 6). The Senna seed extract is a different preparation [20]. Framing caution This is a laboratory and animal composition signal, not a nutrient deficiency and not evidence of dysbiosis in people. It does not support probiotic or supplement recommendations.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production: tissue ATP surplus lowered in obesity models, no depletion reported

Yellow — Low

Evidence in: Tier B

In high-fat-diet mice sennoside A suppressed an abnormal rise in tissue ATP by inhibiting complex I. No study reported reduced ATP or energy output in healthy tissue or in people.

Full detail and limits

Limits on what this shows

Key null findings: No ATP measurement with senna in healthy animals or in people was retrieved. The healthy-rat extract study did not measure ATP [21].
At-risk subgroups: None identified.

Regulatory status

No ATP or energy statement in the label fields retrieved [1][2].

Population evidence

Tier B, sennoside A. Le 2018: liver ATP was increased in steatosis and the effect was reversed by sennoside A; the highlights state it suppressed ATP surplus by inhibiting mitochondrial complex I [15]. Le 2019: ATP elevated in obese-mouse colon tissue and attenuated by sennoside A; in palmitic-acid-treated L-cells ATP rose with lower membrane potential and apoptosis [17]. Summaries read through fetch tools; values, units and group sizes were not retrieved.

Mechanism

Complex I inhibition, with the authors framing the result as correcting an ATP surplus [15][17].

Counter-evidence held on record

Counter-evidence on record Same underlying studies as Mitochondrial burden (see Overlap map); do not count as separate confirmation. A lowered ATP in a disease model is a normalization, which is not the same as an energy deficit. Framing caution This is not an energy-depletion or fatigue claim and gives no basis for energy supplements.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on hemoglobin, hematocrit, red-cell mass or tissue oxygen delivery with senna sennosides in people or animals. This is a disclosed gap.

Full detail and limits

Limits on what this shows

Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to senna sennosides was found to support even a yellow grade, and no circulating oxygen-delivery or anemia claim for senna was located in the consumer documents audited [28][29] to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap on the PubMed channel that answered; secondary channels and consumer-claim searching were tooling-limited. Kept separate from ATP production.

Regulatory status

The two OTC labels retrieved carry no statement on this category in the fields returned [1][2].

Evidence reviewed

PubMed listing 'senna hemoglobin' returned 8 records, all about other Senna species or whole-plant extracts (Senna occidentalis, S. obtusifolia, S. fistula, S. tora), a hemoglobin A1c alopecia paper, and one chemotherapy-constipation senna extract crossover trial seen by title only. Those species and extracts are not the sennoside laxative product and were excluded as not cohort-appropriate. A Senna occidentalis seed hematopoietic toxicity paper (Teles 2015) was seen by title only in the iron listing and not opened. 'Anthraquinone-induced clubbing associated with laxative abuse' (FitzGerald 1983) was seen by title only; clubbing is a clinical sign and not an oxygen-delivery marker. The drug's intended stimulant action is not an oxygen-delivery effect and is not graded here (Hard Rule 2).

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listings 'senna hemoglobin' (8 records, none usable), 'senna iron' (16 records, none usable) and 'senna copper' (6 records, none usable); consumer documents [28][29] read (no oxygen or anemia claim; the iron claim is handled under Fails verification). Network state this review: per the review brief, direct HTTP to PubMed, eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar, Unpaywall, DailyMed and accessdata.fda.gov is blocked by organization network policy (403 on CONNECT) and was neither attempted nor routed around. Through the fetch tool: PubMed search-listing pages answered intermittently with repeated 429 rate-limit rejections (waits of 60 to 110 seconds between queries), and PubMed single-article pages returned blank or bot-check content; Europe PMC REST returned 429 on both attempts; OpenAlex works-search returned 429 on both attempts while OpenAlex single-record lookups by PMID worked; one ScienceDirect page returned 429 and answered on a single retry; NCBI Bookshelf returned a reCAPTCHA page; the DailyMed search page returned no labels and the openFDA label API was used instead; the EMA herbal monograph URL tried returned 404; Crossref, Semantic Scholar and Unpaywall were not attempted; the web-search budget (200 of 200) was already exhausted, so no web search could be run. No email address or other identifying information was sent to any service. See the access note under Sources.

Counter-evidence held on record

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

Iron depleted (also a mandatory category; kept separate from Copper)
Where it comes from: Nutrition consultancy page listing mineral oil, lactulose, MiraLAX and senna (Senokot) together as depleting "Calcium, Iron and Zinc" among others; no citation given [28].
Why it fails: No senna study measured iron, ferritin or iron absorption; PubMed listing 'senna iron' (16 records) returned only plant, metal-content and unrelated papers. The sentence pools unlike agents and carries no senna mechanism, so it fails at every level (Hard Rule 3). Published only as a rebuttal.
Fat-soluble vitamins A, D, E and K depleted
Where it comes from: Same consultancy page [28]; no citation.
Why it fails: No vitamin measurement with senna was located. The mineral oil mechanism (a lipid-phase solvent that carries fat-soluble vitamins out) does not transfer to a stimulant glycoside, and the group sentence is not a cohort test. Stimulant laxatives are not shown to change vitamin status in any retrieved source.
Vitamin B12 and zinc depleted
Where it comes from: Same consultancy page [28]; no citation.
Why it fails: No B12 or zinc measurement with senna was located and no senna mechanism is named. Not supported at any tier.
Unspecified "loss of essential nutritional factors"
Where it comes from: Chronic-use caution in the Drugs.com monograph for senna, which pairs persistent diarrhea, hypokalemia and dehydration with this phrase [4].
Why it fails: It names no nutrient and no measured marker, so it cannot be falsified (Hard Rule 3). The named parts of the sentence are graded separately (potassium, fluid). Published only as a rebuttal of the unnamed remainder.

How the body handles this medication

Activation and absorption: Sennosides are glycosides activated by colonic microorganisms; rhein anthrone is described as the ultimate active form. The professional monograph states minimal absorption after oral dosing, with laxation within 6 to 12 hours (may take 24 hours). The two OTC labels give 6 to 12 hours for the syrup and no pharmacokinetic section.[7] Lemli 1988 abstract; [4] Drugs.com monograph; [1][2] openFDA labels
Metabolism and CYP450: No CYP450 substrate, inducer or inhibitor data were retrieved, and neither label has a pharmacokinetic section: unknown, not absent. In rats, fecal flora from treated animals converted sennoside A to rhein more efficiently than control flora, and rhein accumulated most over time in feces (rat study up to 90 days). A class review lists hydrolysis, glucuronidation and sulfation as the main anthraquinone pathways but gives no sennoside parameters.[8] Cheng 2020 abstract; [9] Wang 2021 review; [1][2]
Elimination and accumulation: The monograph states that absorbed senna undergoes hepatic metabolism and is eliminated in feces via bile and/or in urine, with distribution not fully characterized. Accumulation in renal or hepatic impairment is not stated in any retrieved source.[4] Drugs.com monograph; [9]
Mechanism and renal handling: Contact stimulant: raises colonic mucosal cyclic AMP and alters permeability to promote fluid and ion secretion and motility. WHO describes the A06AB group as agents that mainly inhibit absorption of electrolytes and water. No renal tubular effect is described in the sources retrieved; the potassium effect in dialysis patients was attributed by the trial authors to shorter colonic transit and less potassium reabsorption.[4] Drugs.com monograph; [3] WHO ATC/DDD Index; [10] Nata abstract
Interactions: Labels: none stated in the fields retrieved. Monograph: faster transit may reduce bioavailability of co-administered oral drugs. One case report: raised tacrolimus exposure (2.8-fold AUC) with a Cassia angustifolia product, a drug interaction and not a nutrient one. An abstract states background that senna with digoxin raises toxicity risk through potassium depletion (direction: senna acts on potassium, which then acts on digoxin). No food, mineral or antacid interaction with direction and magnitude was retrieved.[1][2] labels; [4] monograph; [27] Beltra-Pico 2024 abstract
Regulatory identity: WHO ATC A06AB06, senna glycosides (the DDD field was not returned by the fetch tool). OTC labels retrieved: syrup 8.8 mg sennosides per 5 mL (effective 2025-12-11; do not use longer than 1 week unless directed by a doctor) and tablet 15 mg sennosides (effective 2026-05-11); stop and ask a doctor for rectal bleeding or no bowel movement; pregnancy and breast-feeding: ask a health professional. MedlinePlus: not for more than 1 week without medical advice, and not recommended for long-term use in adults 65 and over.[1][2][3][6]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Monitoring
Labs, only if indicated
Serum potassium is the one measure with a Tier A signal [10]. Potassium, with magnesium, calcium, sodium and bicarbonate, is reasonable when use is prolonged or high-dose and accompanied by persistent diarrhea, muscle weakness or palpitations, or when senna is combined with digoxin, diuretics or other potassium-lowering drugs. No routine screening for occasional labeled use is supported by the evidence retrieved. This is a monitoring prompt, not a deficiency claim.
Monitoring
Kidney disease and dialysis
In the dialysis trial potassium fell on senna [10]; decisions about senna and potassium in kidney disease belong with the treating nephrology team, and no potassium dose appears here.
Monitoring
Interaction timing
No separation interval for any nutrient or drug is stated in the retrieved sources, so none is given. Faster transit may lower the bioavailability of co-administered oral drugs [4]; a pharmacist review is sensible for narrow-therapeutic-index medicines, and one case report describes raised tacrolimus levels with a Cassia angustifolia product [27].
Monitoring
At-risk groups
Long-term or concealed high-dose users; people on dialysis; older adults (MedlinePlus advises against long-term use at 65 and over [6]); pregnancy and breast-feeding (labels: ask a health professional [1][2]); children (the monograph advises avoiding use under 2 years [4]; melanosis coli reported in children taking sennosides, secondhand [24]). Renal-impairment accumulation and pediatric nutrient effects: no data retrieved.
Monitoring
Confounders to keep in view
Constipation itself, poor intake, opioids, other laxatives, diuretics, vomiting and eating-pattern changes. Hard Rule 6 presumes confounding by indication, so low levels in a senna user are not attributed to the drug without further evidence.
Monitoring
Supplements
No supplement dose appears anywhere in this dossier, so no upper-intake-level comparison applies. Nothing here supports adding potassium, magnesium, calcium, vitamins, iron, zinc or probiotics because of senna. Doses quoted in mg/kg are animal exposures in cited studies and not recommendations.

Overlap map, to prevent double counting

Mitochondrial burden
Shares evidence with: ATP production; Oxidative stress; Gut microbiome risk
Note: All rest on the same small set of sennoside A studies in high-fat-diet mice from one laboratory [15][16][17]. Le 2019 [17] also supplies the microbiome and ATP findings. Treat as one line of rodent evidence across four entries, not four confirmations.
Oxidative stress
Shares evidence with: Mitochondrial burden; ATP production
Note: [16] gives both the ROS result and the complex I and III result. The healthy-rat null [21] and sennoside B result [22] are separate sources but are abstract-level. The rhein embryo study [23] is a metabolite extrapolation and not shared with the other entries.
Potassium
Shares evidence with: Fluid, sodium and acid-base; Magnesium
Note: The hemodialysis RCT [10] bears on potassium only. The chronic-overuse series [12][13][14] and the case [11] support potassium, fluid and magnesium at once, and the reference text [4][5] supports potassium, fluid and calcium. Treat the abuse literature as one weak line, not three.
Fluid, sodium and acid-base
Shares evidence with: Calcium; Fails verification: unspecified nutritional factors
Note: Same monograph and side-effect reference sentences [4][5]. The rebuttal covers the unnamed remainder of a sentence whose named parts are graded here.
Magnesium
Shares evidence with: Potassium; Fluid, sodium and acid-base
Note: Meyers 1990 [13] is the single source and is also cited for potassium and fluid; its agents are unspecified, so it is class evidence.
Gut microbiome risk
Shares evidence with: Melanosis coli
Note: Rat work [8] links microbial conversion of sennoside A to rhein with melanosis coli, and [19] links microbial change to colon damage at 14 to 21 days. Mechanistic overlap, different outcomes.
Copper
Shares evidence with: Oxygen delivery/utilization; Iron (white)
Note: Independent entries that share only the same PubMed channels and the same absence of retrieved evidence, plus the same excluded other-species Senna papers. No shared source supports any of them.

All references used above

Senna

Findings for this medication

What the research found

Potassium: serum lowering in a hemodialysis RCT (8 weeks); hypokalemia with chronic overuse reported at case level only

Fluid, sodium and acid-base disturbance with chronic overuse (context flag)

Calcium: reference-text caution only, no measurement

Magnesium: class extrapolation from mixed purgative-abuse cases

Melanosis coli: drug tissue effect, not a nutrient

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden: reverse direction, protective in rodent obesity models

💥Oxidative Stress

Oxidative stress: reverse direction in disease models; a pro-oxidant signal only for the rhein metabolite

⚖️Copper and Iron Balance

Copper

🌿Gut Microbiome Risk

Gut microbiome risk: rodent data with mixed direction, no human in vivo study

💨Oxygen and ATP Output

ATP production: tissue ATP surplus lowered in obesity models, no depletion reported

Oxygen delivery/utilization

Claims checked and not supported

Iron depleted (also a mandatory category; kept separate from Copper)

Fat-soluble vitamins A, D, E and K depleted

Vitamin B12 and zinc depleted

Unspecified "loss of essential nutritional factors"

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output